160 related articles for article (PubMed ID: 25277889)
1. CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection.
Chibueze CE; Yoshimitsu M; Arima N
Biochem Biophys Res Commun; 2014 Oct; 453(3):379-84. PubMed ID: 25277889
[TBL] [Abstract][Full Text] [Related]
2. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.
Kozako T; Yoshimitsu M; Akimoto M; White Y; Matsushita K; Soeda S; Shimeno H; Kubota R; Izumo S; Arima N
Hum Immunol; 2011 Nov; 72(11):1001-6. PubMed ID: 21851845
[TBL] [Abstract][Full Text] [Related]
4. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
5. HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection.
Ezinne CC; Yoshimitsu M; White Y; Arima N
PLoS One; 2014; 9(2):e87631. PubMed ID: 24505299
[TBL] [Abstract][Full Text] [Related]
6. The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function.
Rey J; Giustiniani J; Mallet F; Schiavon V; Boumsell L; Bensussan A; Olive D; Costello RT
Eur J Immunol; 2006 Sep; 36(9):2359-66. PubMed ID: 16917959
[TBL] [Abstract][Full Text] [Related]
7. Universal cytotoxic activity of a HTLV-1 Tax-specific T cell clone from an HLA-A*24:02⁺ patient with adult T-cell leukemia against a variety of HTLV-I-infected T-cells.
Tanaka Y; Yamazaki R; Terasako-Saito K; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Sato M; Kimura S; Kikuchi M; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
Immunol Lett; 2014; 158(1-2):120-5. PubMed ID: 24389072
[TBL] [Abstract][Full Text] [Related]
8. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load.
Nagai M; Kubota R; Greten TF; Schneck JP; Leist TP; Jacobson S
J Infect Dis; 2001 Jan; 183(2):197-205. PubMed ID: 11120926
[TBL] [Abstract][Full Text] [Related]
9. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
11. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis.
Saito M; Nakagawa M; Kaseda S; Matsuzaki T; Jonosono M; Eiraku N; Kubota R; Takenouchi N; Nagai M; Furukawa Y; Usuku K; Izumo S; Osame M
J Infect Dis; 2004 Jan; 189(1):29-40. PubMed ID: 14702150
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T Cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease.
Yamano Y; Cohen CJ; Takenouchi N; Yao K; Tomaru U; Li HC; Reiter Y; Jacobson S
J Exp Med; 2004 May; 199(10):1367-77. PubMed ID: 15136590
[TBL] [Abstract][Full Text] [Related]
13. Clonal expansion within CD4+ and CD8+ T cell subsets in human T lymphotropic virus type I-infected individuals.
Eiraku N; Hingorani R; Ijichi S; Machigashira K; Gregersen PK; Monteiro J; Usuku K; Yashiki S; Sonoda S; Osame M; Hall WW
J Immunol; 1998 Dec; 161(12):6674-80. PubMed ID: 9862696
[TBL] [Abstract][Full Text] [Related]
14. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.
Peretz Y; He Z; Shi Y; Yassine-Diab B; Goulet JP; Bordi R; Filali-Mouhim A; Loubert JB; El-Far M; Dupuy FP; Boulassel MR; Tremblay C; Routy JP; Bernard N; Balderas R; Haddad EK; Sékaly RP
PLoS Pathog; 2012; 8(8):e1002840. PubMed ID: 22916009
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
[TBL] [Abstract][Full Text] [Related]
16. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
Front Immunol; 2018; 9():2611. PubMed ID: 30483269
[TBL] [Abstract][Full Text] [Related]
17. The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients.
Nikolova MH; Muhtarova MN; Taskov HB; Kostov K; Vezenkov L; Mihova A; Boumsell L; Bensussan A
Cell Immunol; 2005 Oct; 237(2):96-105. PubMed ID: 16337931
[TBL] [Abstract][Full Text] [Related]
18. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
[TBL] [Abstract][Full Text] [Related]
19. BY55/CD160 cannot be considered a cytotoxic marker in cytomegalovirus-specific human CD8(+) T cells.
Merino J; Ramírez N; Moreno C; Toledo E; Fernández M; Sánchez-Ibarrola A
Clin Exp Immunol; 2007 Jul; 149(1):87-96. PubMed ID: 17425655
[TBL] [Abstract][Full Text] [Related]
20. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
